Targeted pill combo for advanced lung cancer with a specific gene change
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a new targeted pill (JMT101) combined with another targeted pill (osimertinib) to see if it works better than standard chemotherapy for advanced lung cancer with an EGFR exon 20 insertion mutation. It might help if your cancer has this specific gene change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage IIIB, IIIC, or IV non-small cell lung cancer.
- Your cancer has a specific change called EGFR exon 20 insertion.
- You have at least one tumor that can be measured on a scan.
- You have not had any previous systemic treatment for your advanced lung cancer (like chemo or targeted pills).
- You do not have cancer that has spread to the brain causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
This trial tests a new drug combination for a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the combination can help people whose cancer has grown after standard treatments.
This trial tests whether adding chemotherapy to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer that has not responded fully to osimertinib alone. It is for those whose cancer has a particular EGFR mutation and who still have detectable cancer DNA in their blood after starting osimertinib.
This trial tests if adding an injected chemotherapy drug (pemetrexed) to a targeted oral pill (like osimertinib) works better than the pill alone for patients with lung cancer that has spread to the brain and spinal cord lining.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
Hear when a new Local Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.